DE000UL1WM80/ DE000UL1WM80 /
2024-06-03 7:33:52 PM | Chg.-0.020 | Bid2024-06-03 | Ask2024-06-03 | Underlying | Strike price | Expiration date | Option type |
---|---|---|---|---|---|---|---|
2.540EUR | -0.78% | 2.540 Bid Size: 2,500 |
2.570 Ask Size: 2,500 |
MERCK KGAA O.N. | 192.1516 EUR | 2078-12-31 | Put |
GlobeNewswire
5:00 PM
Biolojic Design Enters into a Multi-Target Drug Discovery Collaboration with Merck KGaA, Darmstadt, ...
GlobeNewswire
2:00 PM
Evaxion Presents Positive and Validating Immune Data from Ongoing Phase 2 Trial with AI-Designed EVX...
GlobeNewswire
2:38 AM
Immutep Announces Clinical Collaboration with MSD to Evaluate Efti in Combination with KEYTRUDA® (pe...
GlobeNewswire
05-29
Jeito Capital announces the acquisition by Merck & Co (NYSE: MRK) of its portfolio company EyeBio fo...
GlobeNewswire
05-07
CytomX Therapeutics Announces Clinical Collaboration with Merck to Evaluate CX-801 in Combination wi...
GlobeNewswire
05-06
Press Release Biocartis NV: Biocartis and Merck to Collaborate on Improving Patient Access to Person...
GlobeNewswire
03-04
C4 Therapeutics Announces Strategic Discovery Research Collaboration with Merck KGaA, Darmstadt, Ger...
GlobeNewswire
2023-12-21
Arch Biopartners Receives Approval from Ethics Committee in Turkey to Proceed with Phase II Cardiac ...
GlobeNewswire
2023-12-14
ITM Executes License Agreement to Obtain Worldwide Exclusive License for the Clinical Development an...
GlobeNewswire
2023-10-17
ImmunOs Therapeutics Announces Clinical Trial Collaboration with Merck & Co., Inc., Rahway, NJ, USA